BCL2 and myelodysplastic syndrome: Notably, we observed that even a small subset of BCL-2+ cells may, over time, expand and become the dominant malignant population, an insight echoed by research illustrating that MDS stem cells enriched in anti-apoptotic pathways can outcompete their healthy counterparts [24].